February 23, 2021
9 min read
Source: Healio Interviews
Disclosures: Brown reports scientific advisory board roles with Kite Pharma and Novartis. Gardner reports honoraria from Novartis. Maude reports consultant roles with Kite Pharma and Novartis. Rouce reports honoraria from Kite Pharma/Gilead and Novartis and research funding from Tessa Therapeutics.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.
Adoption of these therapies for treatment of younger patients, however, has been much less widespread.
“There are far fewer centers that offer CAR-T for children,” Rebecca A. Gardner, MD, associate professor in the department of pediatrics at University of Washington and attending physician at Seattle Children’s Hospital, told Cell Therapy Next…